Myocarditis or Pericarditis Following mRNA COVID-19 Vaccination
Eric Weintraub, Matthew E. Oster, Nicola P. Klein
Abstract
describe findings from a population-based cohort study in Ontario, Canada, that used data from a passive vaccine-safety surveillance system to evaluate reported rates of myocarditis or pericarditis following receipt of an mRNA COVID-19 vaccine, mRNA-1273 (Moderna Spikevax) or BNT162b2 (Pfizer-BioNTech Comirnaty). The authors found that reported rates of myocarditis or pericarditis were higher after vaccination with mRNA-1273 compared with BNT162b2 and that for both vaccines, the rate was higher following dose 2 of the primary 2-dose series when
Topics & Concepts
Coronavirus disease 2019 (COVID-19)MyocarditisPericarditis2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)AlleyViral MyocarditisMedicineArtCartographyVirologySurgeryCardiologyPathologyHistoryGeographyArchaeologyInfectious disease (medical specialty)OutbreakDiseaseViral Infections and Immunology ResearchSARS-CoV-2 and COVID-19 ResearchInfective Endocarditis Diagnosis and Management